Ubiquitin‑modified hepatitis B virus core antigen effectively facilitates antigen presentation and enhances cytotoxic T lymphocyte activity via the cytoplasmic transduction peptide in vitro

Song,Linlin; Zhuo,Meng; Tang,Yuyan; Chen,Xiaohua; Yu,Yongsheng; Tang,Zhenghao; Zang,Guoqing

doi:10.3892/mmr.2015.3352

July-2015 Volume 12 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-2015 Volume 12 Issue 1

Full Size Image

Article

Ubiquitin‑modified hepatitis B virus core antigen effectively facilitates antigen presentation and enhances cytotoxic T lymphocyte activity via the cytoplasmic transduction peptide in vitro

Authors:
- Linlin Song
- Meng Zhuo
- Yuyan Tang
- Xiaohua Chen
- Yongsheng Yu
- Zhenghao Tang
- Guoqing Zang
View Affiliations / Copyright

Affiliations: Department of Infectious Disease, Shanghai JiaoTong University Affiliated Sixth People's Hospital, Shanghai 200233, P.R. China
Pages: 289-296
|
Published online on: February 13, 2015

https://doi.org/10.3892/mmr.2015.3352
Expand metrics +

Abstract

Cluster of differentiation (CD)8+ cytotoxic T lymphocytes (CTLs) have a key role in the elimination of hepatitis B virus (HBV)‑infected cells. Ubiquitin (Ub) functions as a marker for protein degradation, which may promote the generation of peptides appropriate for major histocompatibility complex class I presentation, while the HBV core antigen (HBcAg) possesses marked immunogenic properties. However, it remains to be elucidated whether Ub‑modified HBcAg is able to effectively elicit significant CD8+ CTL activity. In order to address this issue, a prokaryotic vector was constructed to express the Ub‑HBcAg‑cytoplasmic transduction peptide (CTP). The fusion protein was successfully expressed and subsequently pulsed into bone‑marrow‑derived dendritic cells (DCs). It was confirmed that with assistance from the cell‑penetrating properties of CTP, the fusion protein was able to directly penetrate into the cytoplasm of DCs. The results revealed that the Ub‑HBcAg‑CTP fusion protein not only increased the expression of surface molecules in DCs and cytokine secretion from proliferating T cells, but also induced T cells to differentiate into specific CTLs and enhanced their antiviral ability. In conclusion, the Ub‑HBcAg‑CTP fusion protein promoted DC maturation, enhanced the presentation of targeting antigens and efficiently induced HBcAg‑specific CTL immune responses in vitro.

View Figures

View References

1	Ganem D and Prince AM: Hepatitis B virus infection - natural history and clinical consequences. New Engl J Med. 350:1118–1129. 2004. View Article : Google Scholar
2	Shepard CW, Simard EP, Finelli L, Fiore AE and Bell BP: Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev. 28:112–125. 2006. View Article : Google Scholar : PubMed/NCBI
3	Raney AK, Hamatake RK and Hong Z: Agents in clinical development for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 12:1281–1295. 2003. View Article : Google Scholar : PubMed/NCBI
4	Rehermann B: Immune responses in hepatitis B virus infection. Semin Liver Dis. 23:21–38. 2003. View Article : Google Scholar : PubMed/NCBI
5	Kakimi K, Isogawa M, Chung J, Sette A and Chisari FV: Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections. J Virol. 76:8609–8620. 2002. View Article : Google Scholar : PubMed/NCBI
6	Steinman RM and Hemmi H: Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol. 311:17–58. 2006.PubMed/NCBI
7	Pozzi LA, Maciaszek JW and Rock KL: Both dendritic cells and macrophages can stimulate naive CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells. J Immunol. 175:2071–2081. 2005. View Article : Google Scholar : PubMed/NCBI
8	Almand B, Resser JR, Lindman B, et al: Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res. 6:1755–1766. 2000.PubMed/NCBI
9	Glickman MH and Ciechanover A: The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev. 82:373–428. 2002.PubMed/NCBI
10	Shabek N and Ciechanover A: Degradation of ubiquitin: the fate of the cellular reaper. Cell Cycle. 9:523–530. 2010. View Article : Google Scholar : PubMed/NCBI
11	Hershko A and Ciechanover A: The ubiquitin system. Annu Rev Biochem. 67:425–479. 1998. View Article : Google Scholar : PubMed/NCBI
12	Warnatsch A, Bergann T and Krüger E: Oxidation matters: the ubiquitin proteasome system connects innate immune mechanisms with MHC class I antigen presentation. Mol Immunol. 55:106–109. 2013. View Article : Google Scholar
13	Burr ML, Boname JM and Lehner PJ: Studying ubiquitination of MHC class I molecules. Methods Mol Biol. 960:109–125. 2013.PubMed/NCBI
14	Schödel F, Moriarty AM, Peterson DL, et al: The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity. J Virol. 66:106–114. 1992.PubMed/NCBI
15	Singh TR, Garland MJ, Cassidy CM, et al: Microporation techniques for enhanced delivery of therapeutic agents. Recent Pat Drug Deliv Formul. 4:1–17. 2010. View Article : Google Scholar
16	Kim D, Jeon C, Kim JH, et al: Cytoplasmic transduction peptide (CTP): new approach for the delivery of biomolecules into cytoplasm in vitro and in vivo. Exp Cell Res. 312:1277–1288. 2006. View Article : Google Scholar : PubMed/NCBI
17	Huang Y, Chen Z, Jia H, Wu W, Zhong S and Zhou C: Induction of Tc1 response and enhanced cytotoxic T lymphocyte activity in mice by dendritic cells transduced with adenovirus expressing HBsAg. Clin Immunol. 119:280–290. 2006. View Article : Google Scholar : PubMed/NCBI
18	Tatu RF, Anuşca DN, Groza SŞ, et al: Morphological and functional characterization of femoral head drilling-derived mesenchymal stem cells. Rom J Morphol Embryol. 55:1415–1422. 2014.
19	Crawford TQ, Ndhlovu LC, Tan A, et al: HIV-1 infection abrogates CD8+ T cell mitogen-activated protein kinase signaling responses. J Virol. 85:12343–12350. 2011. View Article : Google Scholar : PubMed/NCBI
20	Chen JH, Yu YS, Chen XH, Liu HH, Zang GQ and Tang ZH: Enhancement of CTLs induced by DCs loaded with ubiquitinated hepatitis B virus core antigen. World J Gastroenterol. 18:1319–1327. 2012. View Article : Google Scholar : PubMed/NCBI
21	Giermasz AS, Urban JA, Nakamura Y, et al: Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunol Immunother. 58:1329–1336. 2009. View Article : Google Scholar : PubMed/NCBI
22	Wang L, Zou ZQ, Liu CX and Liu XZ: Immunotherapeutic interventions in chronic hepatitis B virus infection: a review. J Immunol Methods. 407:1–8. 2014. View Article : Google Scholar : PubMed/NCBI
23	Tsai SL, Sheen IS, Chien RN, et al: Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications. J Biomed Sci. 10:120–135. 2003. View Article : Google Scholar : PubMed/NCBI
24	Phillips S, Chokshi S, Riva A, Evans A, Williams R and Naoumov NV: CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J Immunol. 184:287–295. 2010. View Article : Google Scholar
25	Schliehe C, Bitzer A, van den Broek M and Groettrup M: Stable antigen is most effective for eliciting CD8⁺ T-cell responses after DNA vaccination and infection with recombinant vaccinia virus in vivo. J Virol. 86:9782–9793. 2012. View Article : Google Scholar : PubMed/NCBI
26	Chiang CL, Balint K, Coukos G and Kandalaft LE: Potential approaches for more successful dendritic cell-based immunotherapy. Expert Opin Biol Ther. Jan 2–2015.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
27	Tavakoli S, Mederacke I, Herzog-Hauff S, et al: Peripheral blood dendritic cells are phenotypically and functionally intact in chronic hepatitis B virus (HBV) infection. Clin Exp Immunol. 151:61–70. 2008. View Article : Google Scholar
28	Op den Brouw ML, Binda RS, van Roosmalen MH, et al: Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology. 126:280–289. 2009. View Article : Google Scholar :
29	Chen HZ, Wu CP, Chao YC and Liu CY: Membrane penetrating peptides greatly enhance baculovirus transduction efficiency into mammalian cells. Biochem Biophys Res Commun. 405:297–302. 2011. View Article : Google Scholar : PubMed/NCBI
30	Schaefer A, Nethe M and Hordijk PL: Ubiquitin links to cytoskeletal dynamics, cell adhesion and migration. Biochem J. 442:13–25. 2012. View Article : Google Scholar : PubMed/NCBI
31	Gao G and Luo H: The ubiquitin-proteasome pathway in viral infections. Can J Physiol Pharmacol. 84:5–14. 2006. View Article : Google Scholar : PubMed/NCBI
32	Wang QM, Kang L and Wang XH: Improved cellular immune response elicited by a ubiquitin-fused ESAT-6 DNA vaccine against Mycobacterium tuberculosis. Microbiol Immunol. 53:384–390. 2009. View Article : Google Scholar : PubMed/NCBI
33	Pal A and Donato NJ: Ubiquitin-specific proteases as therapeutic targets for the treatment of breast cancer. Breast Cancer Res. 16:4612014. View Article : Google Scholar
34	Rodriguez F, Zhang J and Whitton JL: DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J Virol. 71:8497–8503. 1997.PubMed/NCBI
35	Cao T, Lazdina U, Desombere I, et al: Hepatitis B virus core antigen binds and activates naive human B cells in vivo: studies with a human PBL-NOD/SCID mouse model. J Virol. 75:6359–6366. 2001. View Article : Google Scholar : PubMed/NCBI
36	Chen W, Shi M, Shi F, et al: HBcAG-pulsed dendritic cell vaccine induces Th1 polarization and production of hepatitis B virus-specific cytotoxic T lymphocytes. Hepatol Res. 39:355–365. 2009. View Article : Google Scholar : PubMed/NCBI